{
    "nctId": "NCT06300411",
    "briefTitle": "SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery",
    "officialTitle": "A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18 years or older\n* Body weight \\>50kg\n* Have a history of histologically confirmed diagnosis of breast carcinoma or ductal carcinoma in situ, except inflammatory breast cancer.\n* Plan to undergo breast-conserving surgical treatment of breast cancer with curative intent. Adjuvant or neoadjuvant chemotherapy is allowed.\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status \\<2\n* Have adequate organ and bone marrow function at screening\n\nExclusion Criteria:\n\n* Any known contraindication to ketorolac or other non-steroidal anti-inflammatory drugs (NSAIDs)\n* Patients anticipated to require the use of a drain after breast-conserving surgery (BCS)\n* Patients undergoing immediate reconstruction surgery, intraoperative radiation therapy (IORT) or brachytherapy requiring the placement of balloons or catheters during the lumpectomy procedure.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}